- Business Wire•2 days ago
InVivo Therapeutics Holdings Corp. today announced that Health Canada has approved the company’s Investigational Testing Authorization application to commence a clinical study of the Neuro-Spinal Scaffold™ in patients with acute, complete cervical spinal cord injuries .
- Business Wire•4 days ago
InVivo Therapeutics Announces Submission to the FDA of Its Nonclinical Studies Module for the Neuro-Spinal Scaffold™
InVivo Therapeutics Holdings Corp. today announced that it has submitted its first module containing nonclinical studies to the U.S. Food and Drug Administration as part of its Humanitarian Device Exemption modular submission and review process for the Neuro-Spinal Scaffold™.
- Business Wire•5 days ago
InVivo Therapeutics Announces Enrollment of New Patient into the INSPIRE Study at New Jersey’s Cooper Neurological Institute
InVivo Therapeutics Holdings Corp. today announced that a new patient has been enrolled into The INSPIRE Study at the Cooper Neurological Institute , which is part of Cooper University Hospital, a network providing care to Southern New Jersey and the Delaware Valley.
NVIV : Summary for InVivo Therapeutics Holdings Co - Yahoo Finance
InVivo Therapeutics Holdings Corp. (NVIV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Ask||4.05 x 1000|
|Day's Range||4.00 - 4.20|
|52 Week Range||3.80 - 7.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.26|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|